Core Insights - Interest in phased retirement programs is increasing, although formal programs remain rare in the workplace [3][4] - A significant portion of the workforce, particularly older employees, is seeking options for gradual transition out of the workforce [4][5] Company Insights - Abbott offers a "Freedom to Work" program for employees aged 55 and older with over 10 years of service, allowing for reduced work schedules or additional time off [8] - The phased retirement program at Abbott is designed to help employees transition into retirement at their own pace [1] Industry Insights - Only 7% of firms surveyed by the Society for Human Resource Management (SHRM) provide formal phased retirement programs, while about 20% offer informal options [2] - Many older workers are financially unprepared for retirement and prefer to continue working, often delaying retirement due to financial necessity [5][6]

Company Performance - Abbott's stock closed at $115.29, reflecting a +2.74% change from the previous day's closing price, outperforming the S&P 500 which lost 1.04% [1] - Over the past month, Abbott's shares gained 4.46%, surpassing the Medical sector's gain of 0.7% and the S&P 500's gain of 1.75% [1] Upcoming Earnings - Abbott is expected to report an EPS of $1.15, representing a 5.5% increase from the prior-year quarter, with revenue estimated at $11.03 billion, indicating a 6.53% increase year-over-year [2] - For the full year, analysts project earnings of $5.68 per share and revenue of $47.73 billion, marking changes of +10.29% and +7.67% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Abbott reflect shifting business dynamics, with positive revisions indicating analysts' confidence in the company's performance and profit potential [4] - The Zacks Consensus EPS estimate has increased by 0.16% over the past month, and Abbott currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Abbott has a Forward P/E ratio of 19.76, which is lower than the industry average of 20.25, indicating that Abbott is trading at a discount compared to its peers [7] - The company has a PEG ratio of 1.79, aligning with the average PEG ratio of the Medical - Products industry [7] Industry Context - The Medical - Products industry, to which Abbott belongs, has a Zacks Industry Rank of 140, placing it in the bottom 43% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Danone gave its first estimate of the potential cost of the recent recalls of infant formula over a contamination scare https://t.co/WTAEAMBlfg ...

The Paris prosecutor’s office opened probes into allegedly tainted infant formula distributed by Nestlé SA, Danone, Groupe Lactalis and two other brands. https://t.co/yDR4XE5aun ...

Nestlé is ramping up production of infant formula to avert a shortage, after a contamination crisis led the Swiss foodmaker and its rivals to recall hundreds of batches https://t.co/7ot5OVkuOD ...

French authorities are investigating the death of a third baby as part of a widening probe into tainted infant formula https://t.co/cpNnH1mjb1 ...

Danone is recalling more than 120 batches of infant formula in Austria due to possible contamination with the toxin cereulide, the largest callback so far for the French producer amid a months-long crisis for European formula producers https://t.co/mnEJAQr5xp ...

Danone said Friday it is recalling selected batches of its infant formula in line with guidance from Irish food-safety authorities https://t.co/nkeleMzRSY ...

Core Viewpoint - Danone has blocked a batch of infant formula intended for the Singaporean market at the request of the Singapore Food Agency (SFA) [1] Company Summary - Danone is a French food manufacturer that has taken precautionary measures regarding its infant formula products [1] Industry Summary - The action taken by Danone highlights the regulatory oversight in the food industry, particularly concerning infant nutrition products [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from underinvestment and required substantial capital expenditures [4] - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results [4] - The misleading statements about Perrigo's business operations resulted in investor damages when the true details became public [4]